Angiotensin Receptor Antagonists Market, By Type (Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, and Olmesartan), By Application (Hypertension, Cardiovascular Diseases, Kidney Diseases, and Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis and Forecast till 2034

Report Code: PMI159819 | Publish Date: May 2024 | No. of Pages: 170

Global Angiotensin Receptor Antagonists Market Overview

Angiotensin Receptor Antagonists Market was valued at US$ 9.0 billion in 2024 and is projected to grow at a CAGR of 3.6% to reach US$ 12.8 billion by 2034.

Angiotensin receptor antagonists (ARBs), commonly referred to as angiotensin II receptor blockers, are a class of drugs that are primarily employed to treat disorders involving the cardiovascular system and hypertension (high blood pressure).Angiotensin receptor antagonists work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict, leading to increased blood pressure. By inhibiting angiotensin II from binding to its receptors, ARBs cause blood vessels to dilate, which helps to lower blood pressure and reduce the workload on the heart.

Most ARBs available in the angiotensin receptor antagonists market are commonly prescribed for the management of hypertension, either as monotherapy or in combination with other antihypertensive medications. They are also used to treat various other conditions, including heart failure, and diabetic nephropathy (kidney disease), and to protect against cardiovascular events such as heart attacks and strokes in patients at high risk.Some common examples of ARBs present in the angiotensin receptor antagonists market include Losartan (Cozaar), Valsartan (Diovan), and many more. They have been shown to have beneficial effects on cardiovascular outcomes, such as reducing the risk of heart failure and stroke without any added risk of severe long-lasting side effects.

Common side effects may be seen in any medications approved for the angiotensin receptor antagonists market including dizziness, headache, fatigue, and increased potassium levels (hyperkalemia). Rarely, more serious side effects such as allergic reactions, kidney problems, or liver toxicity may occur.

Angiotensin receptor antagonists market is expected to maintain a steady growth trajectory throughout the upcoming forecast period. It is primarily driven by the rising incidence of heart disorders throughout the world due to poor lifestyle choices and a growing elderly population.

According to a 2023 report by the National Institute of Health (NIH), 20.5 million US citizens suffer from coronary artery disease. Globally the number of affected individuals is at approximately 200 million. Of this 110 million are men and 80 million are women. Between 1990 and 2019, the number of cases of CVD nearly doubled from 271 million to 523 million.

Introduction - Angiotensin Receptor Antagonists Market

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Global Angiotensin Receptor Antagonists Market Drivers & Restraints

Drivers of the Angiotensin Receptor Antagonists Market:      

  • Rising prevalence of cardiovascular diseases (CVDs):  Over the last twenty years, there has been a sharp increase in the global incidence of coronary artery diseases. This is partially caused by people's increasingly busy lives, unhealthy habits, and elevated stress levels. These are the main factors driving the market for angiotensin receptor antagonists since these conditions have a well-researched and proven therapy option in angiotensin receptor antagonists, which improve blood flow by expanding and relaxing blood vessels. The World Health Organization projects that by 2025, the number of persons with hypertension alone will have increased to 1.5 billion.
  • Growing geriatric population: As the population ages, there is a greater demand for medications to treat chronic conditions like hypertension and heart failure, which are more common in older adults. Angiotensin Receptor Antagonists Market is expected to witness growth in the upcoming years.
  • Increased awareness of cost-effective preventive healthcare:  There is a growing emphasis on preventive healthcare and early intervention for chronic diseases. Angiotensin receptor antagonists are generally a relatively inexpensive medication, which makes them an attractive option for patients and healthcare systems alike. This leads to more people being diagnosed and treated for hypertension and other conditions that can benefit from ARBs leading to more demand in the Angiotensin Receptor Antagonists Market.
  • Established safety and efficacy profile: Most angiotensin receptor antagonists have a long history of safe and effective use in managing cardiovascular and renal diseases. This well-established track record makes them a trusted option for both doctors and patients.

Restrains in the Angiotensin Receptor Antagonists Market:

  • Safety Concerns: There have been some safety concerns associated with ARBs, such as the risk of birth defects if taken during pregnancy and the possibility of increased potassium levels in the blood. These concerns can lead to patient hesitancy and stricter prescribing guidelines from doctors, which can limit angiotensin receptor antagonists' market growth.
  • Availability of Alternative Treatments: There are other classes of medications available to treat the same conditions as ARBs, such as angiotensin-converting enzyme (ACE) inhibitors. These alternative medications may be just as effective as ARBs for some patients, and they may have a different side effect profile. This can give doctors and patients more treatment options to choose from, which can limit the market for ARBs.
  • Strict Regulatory Requirements: The development and approval process for new ARBs is becoming increasingly complex and expensive. This can discourage pharmaceutical companies from investing in the development of new ARBs, which can limit innovation in the angiotensin receptor antagonists market.

Key Opportunities in Angiotensin Receptor Antagonists Market:

  • Demand for Effective Treatments: There's a continuous need for efficient medications to manage cardiovascular and kidney diseases. ARBs offer a proven track record of effectiveness and are generally well-tolerated by patients.
  • Technological Advancements:  Research and development in the field are leading to the creation of new and improved ARBs with better efficacy and fewer side effects.
  • Focus on Emerging Markets: The Asia Pacific region, with its large and aging population, is expected to see significant growth in ARB demand. Increasing healthcare access and disposable income in these regions will further propel the angiotensin receptor antagonists market.
  • Combination Therapies: Combining ARBs with other medications has shown promise in improving patient outcomes. This trend is likely to continue, creating additional opportunities for the angiotensin receptor antagonists market.

Global Angiotensin Receptor Antagonists Market Segmentations & Regional Insights

Angiotensin Receptor Antagonists Market is segmented based on based on by Type, by Technology and Region.

Type Insight

  • Valsartan- Currently this is the largest segment of the angiotensin receptor antagonists market, its popularity driven by its reduced number of side effects
  • Telmisartan- This is a significantly smaller segment of the market and has a steady outreach since it is known to be highly effective as an ARB
  • Losartan- This is the second largest segment of the angiotensin receptor antagonists market mostly due to its widespread availability and affordability.
  • Irbesartan- This segment is witnessed growth in recent years due to rising demand for medications with lower side effects
  • Azilsartan- This is a niche segment of the market that will witness steady growth in the forecast period due to the ongoing rise in demand for affordable medications for the treatment of CVDs
  • Olmesartan- This is a growing segment of the angiotensin receptor antagonists market which will witness significant growth in emerging markets due to its affordability.

Application Insights

  • Hypertension is the largest application-based segment of the Angiotensin Receptor Antagonists Market which will continue holding the dominant revenue shares of the market in the future.
  • Cardiovascular Diseases- This is the second largest segment of the market catering to a wide range of heart disease-related symptoms. The rising incidence of different CVDs and the need to mitigate the adverse effects of CAD will drive this segment
  • Kidney Diseases- This is a growing segment of the target market driven entirely by the increasing incidence of chronic kidney disorders.
  • Other- This is a niche segment of the Angiotensin Receptor Antagonists Market catering to migraines and sclerodermas.

Regional Insights:

Angiotensin Receptor Antagonists Market Regional Insights:

On region the Angiotensin Receptor Antagonists Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

  • North America market currently holds the dominant market share of the Angiotensin Receptor Antagonists Market and is expected to lead throughout the forecast period due to the high prevalence of chronic diseases leading to more curative approaches. Advanced healthcare infrastructure with well-equipped hospitals and a strong presence of leading pharmaceutical manufacturers are other major growth drivers.
  • Asia Pacific region is the second largest regional market projected to witness a significant growth rate in the forecast period due to factors like rising disposable incomes, increasing government investments in healthcare, and a rapidly growing geriatric population. An increase in a number of cases of CVD and kidney disorders will drive market growth.
  • Europe has a mature Angiotensin Receptor Antagonists Market with a strong focus on product quality and ergonomic design that allows rapid treatment. Stringent regulations and high healthcare spending further contribute to market growth.
  • Latin America region is expected to show steady growth due to developing healthcare sectors, improved access to medical equipment and health tech, and increasing awareness about the benefits of alternatives to ACE inhibitors.
  • Middle East & Africa: The Angiotensin Receptor Antagonists Market in this region is expected to witness significant growth in the coming years, driven by several factors such as the rapidly growing awareness regarding the benefits of these pharmaceuticals with regard to diagnostic accuracy and efficient patient-oriented care

Report Scope:

Attribute

Details

Market Size 2024

US$ 9.0 billion

Projected Market Size 2034

US$ 12.8 billion

CAGR Growth Rate

3.6 %

Base year for estimation  

2023

Forecast period       

2024-2034

Market representation       

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Type-   Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, and Olmesartan

By Application- Hypertension, Cardiovascular Diseases, Kidney Diseases, and Other

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the Angiotensin Receptor Antagonists Market report based on By Type, By Technology and Region:

Angiotensin Receptor Antagonists Market, By Type:

  • Valsartan
  • Telmisartan
  • Losartan
  •  Irbesartan
  • Azilsartan
  • Olmesartan

Angiotensin Receptor Antagonists Market, By Technology:

  • Hypertension
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other

Angiotensin Receptor Antagonists Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global Angiotensin Receptor Antagonists Market Competitive Landscape & Key Players

The key players operating the Angiotensin Receptor Antagonists Market includes Pfizer Inc., Novartis AG, Merck & Co. Ltd., Astra Zeneca Pharmaceuticals LP, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Co., Bayer AG, GSK LLC, Johnson & Johnson, Teva Pharmaceutical Inc.

Key Players - Angiotensin Receptor Antagonists Market

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Global Angiotensin Receptor Antagonists Market Recent News

  • In May 2021, Novartis declared that the FDA had approved Entresto, a novel ACE inhibitor medication, for the management of heart failure. It has been demonstrated that this medication lowers the risk of hospitalization and death in heart failure patients.
  • In November 2020, Pfizer and BioNTech revealed the 95% efficacy of the COVID-19 vaccination in their clinical trial results in November 2020. Being a top manufacturer of ACE inhibitors, Pfizer has benefited greatly from the COVID-19 vaccine's success.

Global Angiotensin Receptor Antagonists Market Company Profile

  • Pfizer, Inc."*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
  • Merck & Co., Ltd.
  • Astra Zeneca Pharmaceuticals LP
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb Co.
  • Bayer AG
  • GSK LLC
  • Johnson & Johnson
  • Teva Pharmaceutical, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

FAQs

Angiotensin Receptor Antagonists Market report segments the market on the basis of type, application, and region.

Emerging trends may include the development of novel ARAs, increased use in cardiovascular conditions beyond hypertension, and ongoing research on the role of the renin-angiotensin system. Opportunities could arise from a growing emphasis on cardiovascular health, the exploration of combination therapies, and potential applications in renal and metabolic conditions.

Key factors may include the prevalence of hypertension and cardiovascular diseases, advancements in cardiovascular research, efforts to improve antihypertensive treatment options, and the recognition of ARAs as effective agents with favorable side effect profiles. Additionally, the use of ARAs in patients with diabetes and kidney diseases contributes to market growth.

Regions typically considered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The dominance of the market may depend on factors such as the prevalence of cardiovascular diseases, healthcare infrastructure, regulatory landscape, and the adoption of antihypertensive medications.

The key players operating the Angiotensin Receptor Antagonists Market includes Pfizer Inc., Novartis AG, Merck & Co. Ltd., Astra Zeneca Pharmaceuticals LP, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Co., Bayer AG, GSK LLC, Johnson & Johnson, Teva Pharmaceutical Inc.